{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:56:06Z","timestamp":1789678566687,"version":"4.0.1"},"reference-count":35,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundamental Fund of Khon Kaen University"},{"name":"National Science Research and Innovation Fund"},{"name":"Research Fund for Supporting Lecturer to Admit High Potential Student to Study and Research on His Expert Program Year 2022","award":["651JH103"],"award-info":[{"award-number":["651JH103"]}]},{"name":"Graduate School, Khon Kaen University, Thailand"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The cytochrome P450 family 3 subfamily A polypeptide 5 (<jats:italic>CYP3A5<\/jats:italic>) gene plays an important role in renal function through its product\u2019s involvement in metabolizing endogenous substances and drugs, including immunosuppressants used following kidney transplantation. A single-nucleotide polymorphism, <jats:italic>CYP3A5*3<\/jats:italic> (rs776746), produces a non-functional variant that may influence progression of chronic kidney disease (CKD) by impairing renal filtration. However, the frequency of the <jats:italic>CYP3A5*3<\/jats:italic> allele in the Thai population and its association with renal parameters remain underexplored. This study aimed to determine the prevalence of <jats:italic>CYP3A5<\/jats:italic> polymorphisms and their association with renal function.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We investigated the distribution of <jats:italic>CYP3A5<\/jats:italic> polymorphisms in 329 northeastern Thai participants, including 205 CKD patients and 124 healthy controls. Genotyping was performed using the TaqMan allelic discrimination assay. Renal function parameters were assessed and compared between <jats:italic>CYP3A5*1<\/jats:italic> and <jats:italic>CYP3A5*3<\/jats:italic> allele carriers.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the entire cohort, the allele frequency of <jats:italic>CYP3A5*3<\/jats:italic> was 63.2%, with genotype frequencies of <jats:italic>CYP3A5*1\/*1<\/jats:italic> (16.7%), <jats:italic>CYP3A5*1\/*3<\/jats:italic> (40.1%), and <jats:italic>CYP3A5*3\/*3<\/jats:italic> (43.2%). There was no significant difference in the <jats:italic>CYP3A5<\/jats:italic> allele frequencies between CKD and control groups. <jats:italic>CYP3A5*3<\/jats:italic> carriers exhibited significantly lower eGFR, urine creatinine and serum creatinine clearance and higher UACR compared to <jats:italic>CYP3A5*1<\/jats:italic> carriers. After adjusting for confounders, <jats:italic>CYP3A5*3<\/jats:italic> remained significantly associated with reduced urine creatinine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study highlights a high prevalence of <jats:italic>CYP3A5<\/jats:italic> polymorphisms in the northeastern Thai population. The association of the <jats:italic>CYP3A5*3<\/jats:italic> allele with renal function parameters underscores the need for further research into the mechanisms by which <jats:italic>CYP3A5<\/jats:italic> affects kidney function, which could inform personalized CKD management strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.7717\/peerj.19424","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:04:03Z","timestamp":1746183843000},"page":"e19424","source":"Crossref","is-referenced-by-count":2,"title":["Alleles of <i>CYP3A5<\/i> and their association with renal function in chronic kidney disease"],"prefix":"10.7717","volume":"13","author":[{"given":"Onnapa","family":"Kongphan","sequence":"first","affiliation":[{"name":"Department of Biomedical Science, Faculty of Graduate School, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-0169","authenticated-orcid":true,"given":"Worachart","family":"Lert-itthiporn","sequence":"additional","affiliation":[{"name":"Chronic Kidney Disease Prevention in the Northeast of Thailand (CKDNET) Project, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubon","family":"Cha\u2019on","sequence":"additional","affiliation":[{"name":"Chronic Kidney Disease Prevention in the Northeast of Thailand (CKDNET) Project, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirirat","family":"Anutrakulchai","sequence":"additional","affiliation":[{"name":"Chronic Kidney Disease Prevention in the Northeast of Thailand (CKDNET) Project, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokwan","family":"Nahok","sequence":"additional","affiliation":[{"name":"Chronic Kidney Disease Prevention in the Northeast of Thailand (CKDNET) Project, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadthanicha","family":"Artkaew","sequence":"additional","affiliation":[{"name":"Chronic Kidney Disease Prevention in the Northeast of Thailand (CKDNET) Project, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanpen","family":"Sriphan","sequence":"additional","affiliation":[{"name":"Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-7771","authenticated-orcid":true,"given":"Apinya","family":"Jusakul","sequence":"additional","affiliation":[{"name":"Chronic Kidney Disease Prevention in the Northeast of Thailand (CKDNET) Project, Khon Kaen University, Khon Kaen, Thailand"},{"name":"The Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"2","key":"10.7717\/peerj.19424\/ref-1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/ndt\/gfy232","article-title":"Elevated lipoxygenase and cytochrome P450 products predict progression of chronic kidney disease","volume":"35","author":"Afshinnia","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.7717\/peerj.19424\/ref-2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/bcp.13980","article-title":"Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients","volume":"85","author":"Anutrakulchai","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.7717\/peerj.19424\/ref-3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00228-003-0594-2","article-title":"CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations","volume":"59","author":"Balram","year":"2003","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.7717\/peerj.19424\/ref-4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.7717\/peerj.19424\/ref-5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1124\/dmd.111.042648","article-title":"CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele","volume":"40","author":"Bolbrinker","year":"2012","journal-title":"Drug Metabolism and Disposition"},{"key":"10.7717\/peerj.19424\/ref-6","doi-asserted-by":"publisher","first-page":"18188","DOI":"10.1038\/s41598-022-22538-w","article-title":"High prevalence of chronic kidney disease and its related risk factors in rural areas of Northeast Thailand","volume":"12","author":"Cha\u2019on","year":"2022","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.19424\/ref-7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1186\/s12889-020-09387-w","article-title":"CKDNET, a quality improvement project for prevention and reduction of chronic kidney disease in the Northeast Thailand","volume":"20","author":"Cha\u2019on","year":"2020","journal-title":"BMC Public Health"},{"issue":"13","key":"10.7717\/peerj.19424\/ref-8","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"The Journal of the American Medical Association"},{"key":"10.7717\/peerj.19424\/ref-9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/PGPM.S107710","article-title":"CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment","volume":"11","author":"Chen","year":"2018","journal-title":"Pharmacogenomics and Personalized Medicine"},{"issue":"5","key":"10.7717\/peerj.19424\/ref-10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jcpt.12835","article-title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review","volume":"44","author":"Dorji","year":"2019","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.7717\/peerj.19424\/ref-11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/bf03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behavior Research Methods"},{"issue":"3","key":"10.7717\/peerj.19424\/ref-12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1681\/ASN.2004070549","article-title":"Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function","volume":"16","author":"Froissart","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.7717\/peerj.19424\/ref-13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","article-title":"Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population","volume":"12","author":"Fukuen","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.7717\/peerj.19424\/ref-14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1152\/japplphysiol.00322.2003","article-title":"CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults","volume":"95","author":"Givens","year":"2003","journal-title":"Journal of Applied Physiology"},{"issue":"2","key":"10.7717\/peerj.19424\/ref-15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5414\/CP202559","article-title":"CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation","volume":"55","author":"Huang","year":"2017","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"5","key":"10.7717\/peerj.19424\/ref-16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney International"},{"issue":"4","key":"10.7717\/peerj.19424\/ref-17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/kisup.2013.79","article-title":"Risk factors for chronic kidney disease: an update","volume":"3","author":"Kazancio\u011flu","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"1","key":"10.7717\/peerj.19424\/ref-18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"Kidney disease: improving global outcomes (KDIGO) 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO CKD Work Group","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"4","key":"10.7717\/peerj.19424\/ref-19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"10","key":"10.7717\/peerj.19424\/ref-20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1124\/dmd.30.10.1108","article-title":"Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA","volume":"30","author":"Koch","year":"2002","journal-title":"Drug Metabolism and Disposition"},{"issue":"6","key":"10.7717\/peerj.19424\/ref-21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/ng.377","article-title":"Multiple loci associated with indices of renal function and chronic kidney disease","volume":"41","author":"K\u00f6ttgen","year":"2009","journal-title":"Nature Genetics"},{"issue":"4","key":"10.7717\/peerj.19424\/ref-22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nature Genetics"},{"issue":"7","key":"10.7717\/peerj.19424\/ref-23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.34067\/KID.0002102021","article-title":"Global perspective on kidney transplantation: Thailand","volume":"2","author":"Larpparisuth","year":"2021","journal-title":"Kidney360"},{"key":"10.7717\/peerj.19424\/ref-24","doi-asserted-by":"publisher","first-page":"848804","DOI":"10.3389\/fphar.2022.848804","article-title":"Adverse drug reactions of antihypertensives and CYP3A5*3 polymorphism among chronic kidney disease patients","volume":"13","author":"Lee","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.7717\/peerj.19424\/ref-25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/jpm11040252","article-title":"Effects of CYP3A5 polymorphism on rapid progression of chronic kidney disease: a prospective, multi-centre study","volume":"11","author":"Lee","year":"2021","journal-title":"Journal of Personalized Medicine"},{"key":"10.7717\/peerj.19424\/ref-26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/PGPM.S291277","article-title":"Association of CYP3A5 gene polymorphisms and amlodipine-induced peripheral edema in Chinese Han patients with essential hypertension","volume":"14","author":"Liang","year":"2021","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"10.7717\/peerj.19424\/ref-27","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1038\/s41598-021-84194-w","article-title":"Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease","volume":"11","author":"Lidberg","year":"2021","journal-title":"Scientific Reports"},{"issue":"2","key":"10.7717\/peerj.19424\/ref-28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.kisu.2017.07.004","article-title":"Genetic and environmental risk factors for chronic kidney disease","volume":"7","author":"Obrador","year":"2017","journal-title":"Kidney International Supplements"},{"issue":"2","key":"10.7717\/peerj.19424\/ref-29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/ajt.13495","article-title":"Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles","volume":"16","author":"Oetting","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.7717\/peerj.19424\/ref-30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ekir.2019.09.013","article-title":"Melding pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in Northern India","volume":"5","author":"Prasad","year":"2020","journal-title":"Kidney International Reports"},{"issue":"6","key":"10.7717\/peerj.19424\/ref-31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/cpt.2563","article-title":"PharmVar GeneFocus: CYP3A5","volume":"112","author":"Rodriguez-Antona","year":"2022","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"12","key":"10.7717\/peerj.19424\/ref-32","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.7717\/peerj.19424\/ref-33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1086\/426406","article-title":"CYP3A variation and the evolution of salt-sensitivity variants","volume":"75","author":"Thompson","year":"2004","journal-title":"American Journal of Human Genetics"},{"issue":"1\u20132","key":"10.7717\/peerj.19424\/ref-34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cca.2008.07.032","article-title":"CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia","volume":"398","author":"Willrich","year":"2008","journal-title":"Clinica Chimica Acta"},{"issue":"1","key":"10.7717\/peerj.19424\/ref-35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacology & Therapeutics"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/19424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19424.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19424.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:04:05Z","timestamp":1746183845000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/19424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":35,"alternative-id":["10.7717\/peerj.19424"],"URL":"https:\/\/doi.org\/10.7717\/peerj.19424","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"article-number":"e19424"}}